These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 34649864)

  • 1. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial.
    Sholzberg M; Tang GH; Rahhal H; AlHamzah M; Kreuziger LB; Áinle FN; Alomran F; Alayed K; Alsheef M; AlSumait F; Pompilio CE; Sperlich C; Tangri S; Tang T; Jaksa P; Suryanarayan D; Almarshoodi M; Castellucci LA; James PD; Lillicrap D; Carrier M; Beckett A; Colovos C; Jayakar J; Arsenault MP; Wu C; Doyon K; Andreou ER; Dounaevskaia V; Tseng EK; Lim G; Fralick M; Middeldorp S; Lee AYY; Zuo F; da Costa BR; Thorpe KE; Negri EM; Cushman M; Jüni P;
    BMJ; 2021 Oct; 375():n2400. PubMed ID: 34649864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
    Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
    Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
    Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
    Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
    INSPIRATION-S Investigators
    BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
    Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
    JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heparin for Moderately Ill Patients with Covid-19.
    Sholzberg M; Tang GH; Rahhal H; AlHamzah M; Kreuziger LB; Ní Áinle F; Alomran F; Alayed K; Alsheef M; AlSumait F; Pompilio CE; Sperlich C; Tangri S; Tang T; Jaksa P; Suryanarayan D; Almarshoodi M; Castellucci L; James PD; Lillicrap D; Carrier M; Beckett A; Colovos C; Jayakar J; Arsenault MP; Wu C; Doyon K; Andreou ER; Dounaevskaia V; Tseng EK; Lim G; Fralick M; Middeldorp S; Lee AYY; Zuo F; da Costa BR; Thorpe KE; Negri EM; Cushman M; Jüni P;
    medRxiv; 2021 Jul; ():. PubMed ID: 34268513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
    ; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
    JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In patients hospitalized with COVID-19, therapeutic- vs. prophylactic-dose heparin did not reduce a composite outcome at 28 d.
    Bikdeli B; Garcia DA
    Ann Intern Med; 2022 Feb; 175(2):JC16. PubMed ID: 35099997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic versus Prophylactic Bemiparin in Hospitalized Patients with Nonsevere COVID-19 Pneumonia (BEMICOP Study): An Open-Label, Multicenter, Randomized, Controlled Trial.
    Marcos-Jubilar M; Carmona-Torre F; Vidal R; Ruiz-Artacho P; Filella D; Carbonell C; Jiménez-Yuste V; Schwartz J; Llamas P; Alegre F; Sádaba B; Núñez-Córdoba J; Yuste JR; Fernández-García J; Lecumberri R;
    Thromb Haemost; 2022 Feb; 122(2):295-299. PubMed ID: 34638151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of P2Y12 Inhibitors on Survival Free of Organ Support Among Non-Critically Ill Hospitalized Patients With COVID-19: A Randomized Clinical Trial.
    Berger JS; Kornblith LZ; Gong MN; Reynolds HR; Cushman M; Cheng Y; McVerry BJ; Kim KS; Lopes RD; Atassi B; Berry S; Bochicchio G; de Oliveira Antunes M; Farkouh ME; Greenstein Y; Hade EM; Hudock K; Hyzy R; Khatri P; Kindzelski A; Kirwan BA; Baumann Kreuziger L; Lawler PR; Leifer E; Lopez-Sendon Moreno J; Lopez-Sendon J; Luther JF; Nigro Maia L; Quigley J; Sherwin R; Wahid L; Wilson J; Hochman JS; Neal MD;
    JAMA; 2022 Jan; 327(3):227-236. PubMed ID: 35040887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19.
    ; ; ; Goligher EC; Bradbury CA; McVerry BJ; Lawler PR; Berger JS; Gong MN; Carrier M; Reynolds HR; Kumar A; Turgeon AF; Kornblith LZ; Kahn SR; Marshall JC; Kim KS; Houston BL; Derde LPG; Cushman M; Tritschler T; Angus DC; Godoy LC; McQuilten Z; Kirwan BA; Farkouh ME; Brooks MM; Lewis RJ; Berry LR; Lorenzi E; Gordon AC; Ahuja T; Al-Beidh F; Annane D; Arabi YM; Aryal D; Baumann Kreuziger L; Beane A; Bhimani Z; Bihari S; Billett HH; Bond L; Bonten M; Brunkhorst F; Buxton M; Buzgau A; Castellucci LA; Chekuri S; Chen JT; Cheng AC; Chkhikvadze T; Coiffard B; Contreras A; Costantini TW; de Brouwer S; Detry MA; Duggal A; Džavík V; Effron MB; Eng HF; Escobedo J; Estcourt LJ; Everett BM; Fergusson DA; Fitzgerald M; Fowler RA; Froess JD; Fu Z; Galanaud JP; Galen BT; Gandotra S; Girard TD; Goodman AL; Goossens H; Green C; Greenstein YY; Gross PL; Haniffa R; Hegde SM; Hendrickson CM; Higgins AM; Hindenburg AA; Hope AA; Horowitz JM; Horvat CM; Huang DT; Hudock K; Hunt BJ; Husain M; Hyzy RC; Jacobson JR; Jayakumar D; Keller NM; Khan A; Kim Y; Kindzelski A; King AJ; Knudson MM; Kornblith AE; Kutcher ME; Laffan MA; Lamontagne F; Le Gal G; Leeper CM; Leifer ES; Lim G; Gallego Lima F; Linstrum K; Litton E; Lopez-Sendon J; Lother SA; Marten N; Saud Marinez A; Martinez M; Mateos Garcia E; Mavromichalis S; McAuley DF; McDonald EG; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Mouncey PR; Murthy S; Nair GB; Nair R; Nichol AD; Nicolau JC; Nunez-Garcia B; Park JJ; Park PK; Parke RL; Parker JC; Parnia S; Paul JD; Pompilio M; Quigley JG; Rosenson RS; Rost NS; Rowan K; Santos FO; Santos M; Santos MO; Satterwhite L; Saunders CT; Schreiber J; Schutgens REG; Seymour CW; Siegal DM; Silva DG; Singhal AB; Slutsky AS; Solvason D; Stanworth SJ; Turner AM; van Bentum-Puijk W; van de Veerdonk FL; van Diepen S; Vazquez-Grande G; Wahid L; Wareham V; Widmer RJ; Wilson JG; Yuriditsky E; Zhong Y; Berry SM; McArthur CJ; Neal MD; Hochman JS; Webb SA; Zarychanski R
    N Engl J Med; 2021 Aug; 385(9):777-789. PubMed ID: 34351722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial.
    Cohen JB; Hanff TC; William P; Sweitzer N; Rosado-Santander NR; Medina C; Rodriguez-Mori JE; Renna N; Chang TI; Corrales-Medina V; Andrade-Villanueva JF; Barbagelata A; Cristodulo-Cortez R; Díaz-Cucho OA; Spaak J; Alfonso CE; Valdivia-Vega R; Villavicencio-Carranza M; Ayala-García RJ; Castro-Callirgos CA; González-Hernández LA; Bernales-Salas EF; Coacalla-Guerra JC; Salinas-Herrera CD; Nicolosi L; Basconcel M; Byrd JB; Sharkoski T; Bendezú-Huasasquiche LE; Chittams J; Edmonston DL; Vasquez CR; Chirinos JA
    Lancet Respir Med; 2021 Mar; 9(3):275-284. PubMed ID: 33422263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
    Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
    Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: results of the COVID-PREVENT randomized controlled trial.
    Rauch-Kröhnert U; Puccini M; Placzek M; Beyer-Westendorf J; Jakobs K; Friebel J; Hein S; Seidel M; Pieske B; Massberg S; Witzenrath M; Zeiher A; Friede T; Anker SD; Landmesser U
    Clin Res Cardiol; 2023 Nov; 112(11):1620-1638. PubMed ID: 37407731
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.
    ; ; ; Lawler PR; Goligher EC; Berger JS; Neal MD; McVerry BJ; Nicolau JC; Gong MN; Carrier M; Rosenson RS; Reynolds HR; Turgeon AF; Escobedo J; Huang DT; Bradbury CA; Houston BL; Kornblith LZ; Kumar A; Kahn SR; Cushman M; McQuilten Z; Slutsky AS; Kim KS; Gordon AC; Kirwan BA; Brooks MM; Higgins AM; Lewis RJ; Lorenzi E; Berry SM; Berry LR; Aday AW; Al-Beidh F; Annane D; Arabi YM; Aryal D; Baumann Kreuziger L; Beane A; Bhimani Z; Bihari S; Billett HH; Bond L; Bonten M; Brunkhorst F; Buxton M; Buzgau A; Castellucci LA; Chekuri S; Chen JT; Cheng AC; Chkhikvadze T; Coiffard B; Costantini TW; de Brouwer S; Derde LPG; Detry MA; Duggal A; Džavík V; Effron MB; Estcourt LJ; Everett BM; Fergusson DA; Fitzgerald M; Fowler RA; Galanaud JP; Galen BT; Gandotra S; García-Madrona S; Girard TD; Godoy LC; Goodman AL; Goossens H; Green C; Greenstein YY; Gross PL; Hamburg NM; Haniffa R; Hanna G; Hanna N; Hegde SM; Hendrickson CM; Hite RD; Hindenburg AA; Hope AA; Horowitz JM; Horvat CM; Hudock K; Hunt BJ; Husain M; Hyzy RC; Iyer VN; Jacobson JR; Jayakumar D; Keller NM; Khan A; Kim Y; Kindzelski AL; King AJ; Knudson MM; Kornblith AE; Krishnan V; Kutcher ME; Laffan MA; Lamontagne F; Le Gal G; Leeper CM; Leifer ES; Lim G; Lima FG; Linstrum K; Litton E; Lopez-Sendon J; Lopez-Sendon Moreno JL; Lother SA; Malhotra S; Marcos M; Saud Marinez A; Marshall JC; Marten N; Matthay MA; McAuley DF; McDonald EG; McGlothlin A; McGuinness SP; Middeldorp S; Montgomery SK; Moore SC; Morillo Guerrero R; Mouncey PR; Murthy S; Nair GB; Nair R; Nichol AD; Nunez-Garcia B; Pandey A; Park PK; Parke RL; Parker JC; Parnia S; Paul JD; Pérez González YS; Pompilio M; Prekker ME; Quigley JG; Rost NS; Rowan K; Santos FO; Santos M; Olombrada Santos M; Satterwhite L; Saunders CT; Schutgens REG; Seymour CW; Siegal DM; Silva DG; Shankar-Hari M; Sheehan JP; Singhal AB; Solvason D; Stanworth SJ; Tritschler T; Turner AM; van Bentum-Puijk W; van de Veerdonk FL; van Diepen S; Vazquez-Grande G; Wahid L; Wareham V; Wells BJ; Widmer RJ; Wilson JG; Yuriditsky E; Zampieri FG; Angus DC; McArthur CJ; Webb SA; Farkouh ME; Hochman JS; Zarychanski R
    N Engl J Med; 2021 Aug; 385(9):790-802. PubMed ID: 34351721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    RECOVERY Collaborative Group
    Lancet Respir Med; 2021 Dec; 9(12):1419-1426. PubMed ID: 34672950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial".
    Tornero C; Vallejo R; Cedeño D; Orduña J; Pastor E; Belaouchi M; Escamilla B; Laredo M; Del Mar Garzando M
    Trials; 2020 Jun; 21(1):576. PubMed ID: 32586395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical characteristics and outcomes of invasively ventilated patients with COVID-19 in Argentina (SATICOVID): a prospective, multicentre cohort study.
    Estenssoro E; Loudet CI; Ríos FG; Kanoore Edul VS; Plotnikow G; Andrian M; Romero I; Piezny D; Bezzi M; Mandich V; Groer C; Torres S; Orlandi C; Rubatto Birri PN; Valenti MF; Cunto E; Sáenz MG; Tiribelli N; Aphalo V; Reina R; Dubin A;
    Lancet Respir Med; 2021 Sep; 9(9):989-998. PubMed ID: 34224674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study.
    Rentsch CT; Beckman JA; Tomlinson L; Gellad WF; Alcorn C; Kidwai-Khan F; Skanderson M; Brittain E; King JT; Ho YL; Eden S; Kundu S; Lann MF; Greevy RA; Ho PM; Heidenreich PA; Jacobson DA; Douglas IJ; Tate JP; Evans SJW; Atkins D; Justice AC; Freiberg MS
    BMJ; 2021 Feb; 372():n311. PubMed ID: 33574135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation.
    Grandone E; Tiscia G; Pesavento R; De Laurenzo A; Ceccato D; Sartori MT; Mirabella L; Cinnella G; Mastroianno M; Dalfino L; Colaizzo D; Vettor R; Intrieri M; Ostuni A; Margaglione M;
    J Thromb Thrombolysis; 2021 Oct; 52(3):772-778. PubMed ID: 33844150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.